BioXcel Therapeutics Stock (NASDAQ: BTAI) stock price, news, charts, stock research, profile.
Open | $1.12 |
Close | $1.08 |
Volume / Avg. | 420.39K / 585.33K |
Day Range | 1.06 - 1.14 |
52 Wk Range | 1.11 - 12.40 |
Market Cap | $40.91M |
P/E Ratio | - |
Dividend Yield | - |
Exchange | NASDAQ |
RSI | 26 |
Short Interest | 5.23% |
Days to Cover | 2.97 |
Name |
---|
Revenue Change |
Gross Change |
EBITDA Change |
EBIT Change |
Earnings Change |
You can purchase shares of BioXcel Therapeutics (NASDAQ:BTAI) through any online brokerage.
Other companies in BioXcel Therapeutics’s space includes: Kezar Life Sciences (NASDAQ:KZR), Estrella Immunopharma (NASDAQ:ESLA), OncoCyte (NASDAQ:OCX), Curis (NASDAQ:CRIS) and BioLine Rx (NASDAQ:BLRX).
There is no analysis for BioXcel Therapeutics.
BioXcel Therapeutics has a consensus price target of $8.20.
The stock price for BioXcel Therapeutics (NASDAQ: BTAI) is $1.09 last updated Today at July 3, 2024 at 2:05 PM EDT.
There are no upcoming dividends for BioXcel Therapeutics.
BioXcel Therapeutics’s Q2 earnings are confirmed for Monday, August 12, 2024.
There is no upcoming split for BioXcel Therapeutics.
BioXcel Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.